Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06450041 · ClinicalTrials.gov registry record · Phase 2
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
A Phase 2 study of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 13
- Study locations
NCT06450041 is a Phase 2 study of Neuroblastoma that is actively recruiting participants, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 62 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (74% lower). The trial reports 13 study locations across 10 states.
The verdict
NCT06450041, a Phase 2 study of Neuroblastoma, is actively recruiting participants, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG GM-CSF
- DRUG Dinutuximab
- DRUG Universal Donor (UD) TGFβi NK Cells
Study Locations (13)
California
- Children's Hospital Los Angeles - Los Angeles
- UCSF Benioff Children's Hospital - San Francisco
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Texas
- University of Texas Southwestern - Dallas
- Cook Children's Medical Center - Fort Worth
Colorado
- Children's Hospital Colorado - Aurora
Illinois
- Comer Children's Hospital, University of Chicago - Chicago
Massachusetts
- Boston Children's Hospital, Dana-Farber Cancer Institute. - Boston
Michigan
- C.S Mott Children's Hospital - Ann Arbor
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2038-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06450041
The ClinicalTrials.gov registry entry for NCT06450041 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (74% lower). The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.
NCT06450041 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT06450041 about?
NCT06450041 is a clinical study titled "NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial". This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
What is the current status of trial NCT06450041?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2024-12-16. Estimated completion is 2038-12.
What conditions does trial NCT06450041 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT06450041?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), GM-CSF (DRUG), Dinutuximab (DRUG), Universal Donor (UD) TGFβi NK Cells (DRUG).
Who is sponsoring clinical trial NCT06450041?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06450041 being conducted?
This trial has 13 study locations across California, Colorado, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.